Bioventus Q4 2021 Earnings Report
Key Takeaways
Bioventus reported a net sales increase of 32.3% year-over-year to $130.4 million in Q4 2021, driven by acquisitions. However, the company experienced a net loss of $1.9 million, compared to a net income of $2.3 million in the prior year. Adjusted EBITDA increased slightly to $28.5 million from $28.2 million in the prior year.
Net sales increased by 32.3% year-over-year, reaching $130.4 million.
Net loss was ($1.9) million, a decrease compared to the prior year's net income of $2.3 million.
Adjusted EBITDA increased slightly to $28.5 million.
International net sales increased significantly by 71.0% year over year.
Bioventus
Bioventus
Bioventus Revenue by Geographic Location
Forward Guidance
For the full year 2022, Bioventus expects net sales between $545 million and $565 million, representing a year-over-year growth of approximately 26% to 31%. Adjusted EBITDA is projected to be between $94 million and $107 million, compared to $80.8 million for 2021.
Positive Outlook
- Net sales are expected to grow by approximately 26% to 31% year-over-year.
- Adjusted EBITDA is projected to increase compared to the previous year.
- Focus on achieving double-digit organic revenue growth.
- Delivery on cost-synergy commitments.
- Completion of the anticipated acquisition of CartiHeal.
Challenges Ahead
- The company is not providing guidance for adjusted diluted earnings per share due to the uncertainty of the timing for its potential CartiHeal acquisition.
- Inability to predict with reasonable certainty the impact and timing of acquisition-related expenses.
- Uncertainty regarding accounting fair-value adjustments.
- Dependence on a limited number of products.
- The severity and duration of the COVID-19 pandemic are outside of the Company’s control and could cause the Company’s future operating results to be different from its current expectations, particularly if the impact of the pandemic worsens.
Revenue & Expenses
Visualization of income flow from segment revenue to net income